Doctor profile · Federal record
Dr. David Andorsky, MD
Hematology & Oncology Physician (CMS: Hematology/Oncology) · Hematology & Oncology Physician · Boulder, CO
- NPI 1609061837
- Accepts Medicare
- MIPS 81.5 / 100 · 2023
- 24 yrs in practice
- Licensed in 2 states
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
4715 Arapahoe Ave
Boulder, CO 803031385
(303) 385-2000
fax (303) 444-1839 - Mailing address
-
7951 E Maplewood Ave Ste 300
Greenwood Village, CO 801114726
Credentials & registration
- NPI registered
- September 2007 — 19 yrs on file
- Profile last updated
- February 27, 2012
- Year of graduation
- 2002 — 24 yrs since
- Specialty taxonomy
- 207RH0003X — NUCC code
- State licenses (2)
- Colorado #48556 · California #A90997
- Medicaid
- CO #99275261
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1609061837. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
47,412
Distinct HCPCS
10
Medicare allowed
$1,125,580
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
Q0138 |
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 12,750 | 19 | $1 | |
J9144 |
Injection, daratumumab, 10 mg and hyaluronidase-fihj | 7,560 | 11 | $48 | |
J9271 |
Injection, pembrolizumab, 1 mg | 6,900 | 11 | $54 | |
J1453 |
Injection, fosaprepitant, 1 mg | 6,150 | 18 | $0 | |
J1756 |
Injection, iron sucrose, 1 mg | 5,800 | 14 | $0 | |
J1568 |
Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 2,960 | 11 | $42 | |
J1100 |
Injection, dexamethasone sodium phosphate, 1 mg | 1,226 | 39 | $0 | |
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 554 | 220 | $125 | |
J2469 |
Injection, palonosetron hcl, 25 mcg | 530 | 24 | $1 | |
J1626 |
Injection, granisetron hydrochloride, 100 mcg | 511 | 18 | $0 |
In context: peer comparison
Among 3 peers in Boulder Hematology & Oncology Physician, average services per provider: 1,184. This provider delivers 40× the peer median.Open Payments
Industry payments received
All-time total
$5,603
Transactions
8
Manufacturers
7
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| F. Hoffmann-la Roche Ag | 1 | $2,280.00 | |
| Ipsen Bioscience INC. | 1 | $1,230.00 | |
| Abbvie INC. | 2 | $1,094.11 | |
| Novartis Pharmaceuticals Corporation | 1 | $787.50 | |
| AstraZeneca Pharmaceuticals Lp | 1 | $135.00 | |
| Karyopharm Therapeutics INC. | 1 | $50.53 | |
| Janssen Pharmaceuticals, INC | 1 | $25.72 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
604
Patients
84
Total drug cost
$3,019,247
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Eliquis (Apixaban) | Brand | 85 | 18 | $81,273 |
| Anastrozole | Generic | 66 | 19 | $2,222 |
| Gabapentin | Generic | 48 | 11 | $943 |
| Acyclovir | Generic | 46 | 13 | $1,101 |
| Prednisone | Generic | 41 | 12 | $295 |
| Brukinsa (Zanubrutinib) | Brand | 39 | 0 | $598,534 |
| Ibrance (Palbociclib) | Brand | 38 | 0 | $624,561 |
| Tamoxifen Citrate | Generic | 38 | 11 | $1,023 |
| Abiraterone Acetate | Generic | 35 | 0 | $107,561 |
| Calquence (Acalabrutinib Maleate) | Brand | 35 | 0 | $552,938 |
Hospital affiliations
Frequently asked questions
What is Dr. David Andorsky's medical specialty?
Dr. David Andorsky practices Hematology & Oncology Physician in Boulder, CO.
Where does Dr. David Andorsky practice?
Dr. David Andorsky practices at 4715 Arapahoe Ave, Boulder, CO 803031385. Office phone: 3033852000.
What is Dr. David Andorsky's NPI?
Dr. David Andorsky's National Provider Identifier (NPI) is 1609061837, issued by NPPES.
Does Dr. David Andorsky accept Medicare assignment?
Yes. Dr. David Andorsky accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. David Andorsky commonly perform?
Top Medicare-reported procedures in 2023: Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS Q0138); Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS J9144); Injection, pembrolizumab, 1 mg (HCPCS J9271). Source: CMS Medicare Physician & Other Practitioners file.